

Supplementary data

The DIAMORFOSIS (DIagnosis and Management Of lung cancer and FibrOSIS) survey. International survey and call for consensus.

Argyris Tzouvelekis¹, Katerina Antoniou², Michael Kreuter^{3,4}, Matthew Evison⁵, Torsten G Blum⁶, Venerino Poletti⁷, Bogdan Grigoriu⁸, Carlo Vancheri⁹, Paolo Spagnolo¹⁰, Theodoros Karampitsakos¹, Francesco Bonella¹¹, Athol Wells¹², Ganesh Raghu¹³, Maria Molina-Molina¹⁴, Daniel Culver¹⁵, Elisabeth Bendstrup¹⁶, Nesrin Mogulkoc¹⁷, Stefano Elia¹⁸, Jacques Cadranel¹⁹, Demosthenes Bouros²⁰

¹ Department of Internal and Respiratory Medicine, Medical School University of Patras, Greece; ²Department of Respiratory Medicine, University of Crete, Greece; ³Center for Interstitial and Rare Lung Diseases, Pneumology, Thoraxklinik, University of Heidelberg, Heidelberg, Germany; ⁴German Center for Lung Research, Heidelberg, Germany; ⁵Manchester Thoracic Oncology Centre, Wythenshawe Hospital, Manchester University NHS Foundation Trust, Manchester, UK; ⁶Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany; ⁷ Department of Thoracic Diseases, "GB. Morgagni" Hospital, Forlì, Italy; ⁸ Service des Soins Intensifs et Urgences Oncologiques & Oncologie thoracique Institut Jules Bordet, Centre des Tumeurs de l'Université Libre de Bruxelles (ULB), Belgium; ⁹Regional Referral Centre for Rare Lung Diseases, A. O. U. "Policlinico-Vittorio Emanuele" Dept. Of Clinical and Experimental Medicine, University of Catania, Italy; ¹⁰ Respiratory Disease Unit, Department of Cardiac Thoracic, Vascular Sciences and Public Health, University of Padova, Italy; ¹¹ Dept of Pneumology and Allergy, Ruhrlandklinik Medical Faculty, University of Duisburg-Essen, Essen, Germany; ¹² Interstitial Lung Disease Unit, Department of Respiratory Medicine, Royal Brompton and Harefield NHS Foundation Trust, London, UK; ¹³ Center for Interstitial Lung Disease, University of Washington, Seattle, WA, USA; ¹⁴ Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain; ¹⁵Cleveland Clinic, Respiratory Institute, Cleveland, OH, USA; ¹⁶Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Denmark. ¹⁷Department of Pulmonology, Faculty of Medicine, Ege University; İzmir-Turkey; ¹⁸ Thoracic Surgery Unit, Tor Vergata University, Rome, Italy; ¹⁹Service de Pneumologie, APHP, Hôpital Tenon and Sorbonne Université, Paris, France; ²⁰First Academic Department of Respiratory Medicine, National and Kapodistrian University of Athens, Greece

Correspondence:

Argyris Tzouvelekis MD, MSc, PhD

Associate Professor of Internal and Respiratory Medicine

Medical School, University of Patras, Greece

argyrios.tzouvelekis@fleming.

Search terminology:

Idiopathic pulmonary fibrosis and lung cancer

idiopathic pulmonary fibrosis and lung cancer medical specialty,

idiopathic pulmonary fibrosis and lung cancer experience,

idiopathic pulmonary fibrosis and lung cancer hospital,

idiopathic pulmonary fibrosis and lung cancer patients,

idiopathic pulmonary fibrosis and lung cancer incidence,

idiopathic pulmonary fibrosis and lung cancer multidisciplinary team,

idiopathic pulmonary fibrosis and lung cancer management,

idiopathic pulmonary fibrosis and lung cancer diagnostic modality,

idiopathic pulmonary fibrosis and lung cancer histologic subtype,

idiopathic pulmonary fibrosis and lung cancer anatomic location,

idiopathic pulmonary fibrosis and lung cancer median latency time of diagnosis,

idiopathic pulmonary fibrosis and lung cancer percentage,

idiopathic pulmonary fibrosis and lung cancer percentage of other cancer,

idiopathic pulmonary fibrosis and lung cancer common type of other malignancy,

idiopathic pulmonary fibrosis and lung cancer contraindication,

idiopathic pulmonary fibrosis and lung cancer radiotherapy,

idiopathic pulmonary fibrosis and lung cancer chemotherapy,

idiopathic pulmonary fibrosis and lung cancer advanced stage,

idiopathic pulmonary fibrosis and lung cancer antifibrotics,

idiopathic pulmonary fibrosis and lung cancer safety precautions,

idiopathic pulmonary fibrosis and lung cancer surgical lung interventions,

idiopathic pulmonary fibrosis and lung cancer surgery,

idiopathic pulmonary fibrosis and lung cancer operable nodule,

idiopathic pulmonary fibrosis and lung cancer metastatic disease,

idiopathic pulmonary fibrosis and lung cancer treatment,

idiopathic pulmonary fibrosis mild to moderate disease,

idiopathic pulmonary fibrosis moderate to severe disease,

lung cancer stage,

idiopathic pulmonary fibrosis and lung cancer mediastinal lymphadenopathy,

idiopathic pulmonary fibrosis and lung cancer diagnostic step,

idiopathic pulmonary fibrosis and lung cancer diagnosis,

idiopathic pulmonary fibrosis and lung cancer management,

idiopathic pulmonary fibrosis and lung cancer consensus statement